|
Sedentariness
|
Alcohol
|
| What are sedentariness and physical activity and how are they measured? |
What are safe alcohol limits in older people? |
| Are older people more sedentary? |
How can the cardioprotective effect of alcohol be explained? |
| Is sedentariness compensated by physical activity? |
What are safe alcohol limits in older people with ischemic heart disease? |
| What is the importance of sedentariness in cardiovascular risk in older adults? |
How much does alcohol consumption contribute to heart disease in older people? |
| How much does sedentariness contribute to all-cause mortality in older adults? |
How does alcohol consumption affect peripheral vascular disease in older adults? |
| How much does sedentariness influence cardiovascular mortality in older adults? |
Does alcohol affect the risk of AF in older adults? |
| How much does exercise reduce cardiovascular risk in older adults? |
How does alcohol consumption influence the risk of stroke in older adults? |
| How do frailty or functional status worsen prognosis of cvrf in older adults? |
Does alcohol consumption influence the prognosis of AF in older adults? |
| Do CVRF worsen prognosis in elderly patients with frailty or functional decline? |
What is the relationship between alcohol consumption and hypertension in older adults? |
| Is it worth reducing sedentariness in older adults? |
What is the relationship between alcohol consumption and dm in older adults? |
| How can sedentariness be decreased in older adults? |
How much does alcohol consumption influence mortality in older adults with heart failure? |
| What physical activity is recommended in older adults and how should it be prescribed? |
How does alcohol interact with drug therapy for CVRF? |
|
Hypertension
|
Obesity and metabolic syndrome
|
| What are the SBP and DPB targets in older patients with hypertension? |
How much/how do obesity and MS influence cardiovascular risk in older adults? |
| How does frailty influence the management of hypertension in older adults? |
What is the contribution of obesity/MS to cardiovascular mortality in older adults? |
| How does frailty or functional status worsen prognosis of hypertension in older adults? |
What is the contribution of obesity/MS in cardiovascular morbidity in older adults? |
| Does frailty or functional decline worsen prognosis of hypertension in older patients? |
Does frailty or functional decline worsen outcome of obesity in older patients? |
| What effect does exercise have in older patients with hypertension? |
What is the non-pharmacological treatment of older people with obesity and/or MS? |
| Do comorbidity and other factors influence the management of hypertension? |
What are the particular features of the management of older people with obesity and frailty or functional decline? |
| What is the most effective drug therapy for hypertension in older adults? |
Are treatment goals the same as in young adults? |
| How do persons older than 80 years respond to antihypertensive treatment? |
How can a healthy diet be encouraged in older adults? |
| What are the specific therapeutic options for the treatment of hypertension in older adults? |
|
| What are the adverse effects of drug therapy for hypertension in older adults? |
Dyslipidemia
|
| What are the most common events in frail or dependent older adults with hypertension? |
What are the considerations of the management of dislipidemia in older patients? |
|
Are high cholesterol values a sign of healthy aging? |
|
Type 2 diabetes mellitus
|
Are treatment targets the same in older and younger adults? |
| What are the therapeutic targets in older people with DM2? |
How does the management of dyslipidemia in older adults differ from that in younger adults? |
| What is the therapeutic target in older adults with frailty or functional decline and DM2? |
What are the specific considerations of the management of dyslipidemia in older adults with frailty and functional decline? |
Does frailty or functional decline worsen prognosis of DM2 in older patients?
|
What adverse effects can be expected with statin therapy in older adults? |
| How does frailty or functional status worsen prognosis of DM2 in older adults? |
Is statin therapy indicated for cardiovascular disease prevention in older adults? |
| Review of pharmacological recommendations: metformin |
Does statin therapy prevent cardiovascular risk and mortality in older adults with or without DM2? |
| Review of pharmacological recommendations in older people with DM2: pioglitazone |
What is the effect of pravastatin use versus routine care in older adults? |
| Review of pharmacological recommendations in older people with DM2: sulfonylureas |
|
| Review of pharmacological recommendations in older people with DM2: meglitinides |
Smoking
|
| Review of pharmacological recommendations in older people with DM2: glp-1 receptor antagonist |
Does smoking affect quality of life in older adults? |
| Review of pharmacological recommendations in older people with DM2: dpp4 inhibitors |
Does smoking affect cardiovascular disease in older adults? |
| Review of pharmacological recommendations in older people with DM2: alpha-glucosidase inhibitors |
Does smoking influence cognition in older adults? |
| Review of pharmacological recommendations in older people with DM2: insulin |
Does smoking affect mortality in older adults? |
| What is the risk of overtreatment in older people with DM2? |
How do frailty or functional decline worsen outcome of smoking in older patients? |
| How do these therapeutic options modify comorbidities (CKD, HF)? |
Do frailty or functional decline worsen outcome of smoking in older patients? |
| What differences are there between intensive versus standard glycemic control in older adults? |
Therefore, is smoking cessation beneficial in older age? |
|
Are smoking cessation interventions effective in older adults? |
